{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:33:55Z","timestamp":1793745235779,"version":"4.6.1"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PID2021-126051OB-C41"],"award-info":[{"award-number":["PID2021-126051OB-C41"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Government of Arag\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218216","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:29:12Z","timestamp":1765326552000},"page":"218216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Tumor microenvironment in glioblastoma: The central role of the hypoxic\u2013necrotic core"],"prefix":"10.1016","volume":"639","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-2041","authenticated-orcid":false,"given":"Clara","family":"Bayona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Ran\u0111elovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib2","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2025.218216_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.semcancer.2018.07.006","article-title":"Comparison of glioblastoma (GBM) molecular classification methods","volume":"53","author":"Lee","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.canlet.2025.218216_bib5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1586\/14737159.2015.1087315","article-title":"Emerging circulating biomarkers in glioblastoma: promises and challenges","volume":"15","author":"Touat","year":"2015","journal-title":"Expert Rev. Mol. Diagn"},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib6","first-page":"381","article-title":"Brain and other central nervous system tumor statistics, 2021","volume":"71","author":"Miller","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.218216_bib7","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"14","author":"McKinnon","year":"2021","journal-title":"BMJ"},{"issue":"32","key":"10.1016\/j.canlet.2025.218216_bib8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.14694\/EdBook_AM.2012.32.48","article-title":"Glioblastoma: biology, genetics, and behavior","author":"Brat","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.canlet.2025.218216_bib10","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","article-title":"Glioblastoma heterogeneity at single cell resolution","volume":"42","author":"Eisenbarth","year":"2023","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/01.jnen.0000235118.75182.94","article-title":"Correlation among pathology, genotype, and patient outcomes in glioblastoma","volume":"65","author":"Homma","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10555-021-09997-9","article-title":"Glioma: molecular signature and crossroads with tumor microenvironment","volume":"41","author":"Barthel","year":"2022","journal-title":"Cancer Metastasis Rev."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/156800909788166637","article-title":"Hypoxia helps glioma to fight therapy","volume":"9","author":"Amberger-Murphy","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112547","article-title":"A HIF1A\/miR-485\u20135p\/SRPK1 axis modulates the aggressiveness of glioma cells upon hypoxia","volume":"402","author":"Cheng","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00005072-200606000-00001","article-title":"FPseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis","volume":"65","author":"Rong","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"10","key":"10.1016\/j.canlet.2025.218216_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.humpath.2015.06.008","article-title":"Hypoxia-mediated cancer stem cells in pseudopalisades with activation of hypoxia-inducible factor-1\u03b1\/Akt axis in glioblastoma","volume":"46","author":"Inukai","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2025.218216_bib17","doi-asserted-by":"crossref","first-page":"now230","DOI":"10.1093\/neuonc\/now230","article-title":"Glioblastoma on a microfluidic chip: generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events","author":"Ayuso","year":"2017","journal-title":"Neuro Oncol."},{"issue":"83","key":"10.1016\/j.canlet.2025.218216_bib18","first-page":"221","article-title":"Advances and challenges in the treatment of glioblastoma: a clinician's perspective","volume":"15","author":"Mrugala","year":"2013","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12964-017-0194-x","article-title":"Crosstalk between glial and glioblastoma cells triggers the \u201cgo-or-grow\u201d phenotype of tumor cells","volume":"15","author":"Oliveira","year":"2017","journal-title":"Cell Commun. Signal."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/0008-5472.CAN-03-2073","article-title":"Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population","volume":"64","author":"Brat","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib21","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1038\/s41467-023-39933-0","article-title":"Spatial cellular architecture predicts prognosis in glioblastoma","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat. Commun."},{"issue":"49","key":"10.1016\/j.canlet.2025.218216_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","article-title":"Alleviating hypoxia to improve cancer immunotherapy","volume":"42","author":"Fan","year":"2023","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00401-021-02401-4","article-title":"Necrotic reshaping of the glioma microenvironment drives disease progression","volume":"143","author":"Markwell","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib24","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.3390\/ijms21082660","article-title":"Hypoxia, inflammation and necrosis as determinants of glioblastoma cancer stem cells progression","volume":"21","author":"Papale","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218216_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib26","article-title":"Tumor microenvironment in glioblastoma: current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib27","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2016.4952","article-title":"Glioblastoma multiforme: effect of hypoxia and hypoxia inducible factors on therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41467-018-08033-9","article-title":"Coordinative metabolism of glutamine carbon and nitrogen in proliferating cancer cells under hypoxia","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"issue":"3191","key":"10.1016\/j.canlet.2025.218216_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41419-025-07335-3","article-title":"Involvement of p38 MAPK and MAPKAPK2 in promoting cell death and the inflammatory response to ischemic stress associated with necrotic glioblastoma","volume":"16","author":"Kim","year":"2025","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib31","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/s41418-021-00802-2","article-title":"\u03b2-arrestin 2 stimulates degradation of HIF-1\u03b1 and modulates tumor progression of glioblastoma","volume":"28","author":"Bae","year":"2021","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/cells6040045","article-title":"The role of hypoxia in glioblastoma invasion","volume":"6","author":"Monteiro","year":"2017","journal-title":"Cells"},{"issue":"6733","key":"10.1016\/j.canlet.2025.218216_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib34","first-page":"3742","article-title":"Extracellular matrix in glioblastoma: opportunities for emerging therapeutic approaches","volume":"11","author":"Mohiuddin","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2025.218216_bib35","doi-asserted-by":"crossref","first-page":"9276","DOI":"10.1021\/am402097j","article-title":"Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels","volume":"5","author":"Rao","year":"2013","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3171\/2016.6.JNS152797","article-title":"Association of collagen architecture with glioblastoma patient survival","volume":"126","author":"Pointer","year":"2017","journal-title":"J. Neurosurg."},{"issue":"5\u20136","key":"10.1016\/j.canlet.2025.218216_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/ten.tea.2020.0110","article-title":"Matrix stiffness modulates patient-derived glioblastoma cell fates in three-dimensional hydrogels","volume":"27","author":"Wang","year":"2021","journal-title":"Tissue Eng."},{"key":"10.1016\/j.canlet.2025.218216_bib38","unstructured":"Bayona C, Olaizola-Rodrigo C, Sharko V, Ashrafi M, Barrio J del, Doblar\u00e9 M, et al. A novel multicompartment barrier-free microfluidic device reveals the impact of extracellular matrix stiffening and temozolomide on immune-tumor interactions in glioblastoma. Small(n\/a):2409229.."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib39","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/cancers12113331","article-title":"Cancer extracellular matrix proteins regulate tumour immunity","volume":"12","author":"Gordon-Weeks","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.218216_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ceb.2015.06.006","article-title":"The regulation of immune cell trafficking by the extracellular matrix","volume":"36","author":"Hallmann","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.canlet.2025.218216_bib42","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib43","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1038\/s41598-024-56102-5","article-title":"Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines","volume":"14","author":"Marallano","year":"2024","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular States, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.canlet.2025.218216_bib45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41556-018-0183-3","article-title":"A tension-mediated glycocalyx\u2013integrin feedback loop promotes mesenchymal-like glioblastoma","volume":"20","author":"Barnes","year":"2018","journal-title":"Nat. Cell Biol."},{"issue":"23","key":"10.1016\/j.canlet.2025.218216_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316887","article-title":"Hypoxic effects on matrix metalloproteinases' expression in the tumor microenvironment and therapeutic perspectives","volume":"24","author":"Gonzalez-Avila","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218216_bib47","doi-asserted-by":"crossref","unstructured":"J. Collado, L. Boland, J.T. Ahrendsen, J. Miska, C. Lee-Chang, Understanding the glioblastoma tumor microenvironment: leveraging the extracellular matrix to increase immunotherapy efficacy, Front. Immunol. (15) (2024 Feb 6) 1336476.","DOI":"10.3389\/fimmu.2024.1336476"},{"issue":"26","key":"10.1016\/j.canlet.2025.218216_bib48","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/onc.2013.305","article-title":"Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice","volume":"33","author":"Serres","year":"2014","journal-title":"Oncogene"},{"issue":"27","key":"10.1016\/j.canlet.2025.218216_bib49","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1038\/s41388-020-1348-7","article-title":"GBP2 enhances glioblastoma invasion through Stat3\/fibronectin pathway","volume":"39","author":"Yu","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib50","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<1032::AID-IMMU1032>3.0.CO;2-W","article-title":"TGF-\u03b2-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells","volume":"29","author":"M\u00fcnz","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.gt.3300709","article-title":"Decorin gene transfer-mediated suppression of TGF-\u03b2 synthesis abrogates experimental malignant glioma growth in vivo","volume":"5","author":"St\u00e4nder","year":"1998","journal-title":"Gene Ther."},{"issue":"12","key":"10.1016\/j.canlet.2025.218216_bib52","first-page":"3810","article-title":"Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition","volume":"117","author":"Higgins","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218216_bib53","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","article-title":"Immune microenvironment in glioblastoma subtypes","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib54","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/life12081225","article-title":"Macrophages in glioblastoma development and therapy: a double-edged sword","volume":"12","author":"Wu","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.canlet.2025.218216_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384249","article-title":"Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments","volume":"15","author":"Feldman","year":"2024","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.canlet.2025.218216_bib56","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.3390\/cancers13174255","article-title":"Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy","volume":"13","author":"Andersen","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib57","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.3390\/ijms22115775","article-title":"Macrophages\/microglia in the glioblastoma tumor microenvironment","volume":"22","author":"Ma","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/brain\/awaa382","article-title":"Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma","volume":"144","author":"Ross","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.canlet.2025.218216_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.canlet.2025.218216_bib61","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib62","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/stem.2393","article-title":"Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion","volume":"34","author":"Otvos","year":"2016","journal-title":"Stem Cell."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib63","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/neuonc\/nov280","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients","volume":"18","author":"Dubinski","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib64","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12974-024-03222-4","article-title":"Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy","volume":"21","author":"Wen","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.canlet.2025.218216_bib65","article-title":"Neutrophils in glioma microenvironment: from immune function to immunotherapy","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.canlet.2025.218216_bib66","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib67","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ccell.2024.08.008","article-title":"Glioblastoma induces the recruitment and differentiation of dendritic-like \u201chybrid\u201d neutrophils from skull bone marrow","volume":"42","author":"Lad","year":"2024","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.canlet.2025.218216_bib68","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-12-2801","article-title":"Regulatory T cells move in when gliomas say \u201cI DO\u201d","volume":"18","author":"Choi","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-007-0336-x","article-title":"Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy","volume":"57","author":"Jordan","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"22","key":"10.1016\/j.canlet.2025.218216_bib70","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib71","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro Oncol."},{"issue":"42","key":"10.1016\/j.canlet.2025.218216_bib72","doi-asserted-by":"crossref","first-page":"36694","DOI":"10.1074\/jbc.M111.292540","article-title":"Glioma-derived T cell Immunoglobulin- and mucin domain-containing Molecule-4 (TIM4) contributes to tumor tolerance","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.canlet.2025.218216_bib73","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib74","doi-asserted-by":"crossref","first-page":"937","DOI":"10.32604\/or.2024.056436","article-title":"Microglia and brain macrophages are differentially associated with tumor necrosis in glioblastoma: a link to tumor progression","volume":"33","author":"Loh","year":"2025","journal-title":"Oncol. Res."},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib75","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/0008-5472.CAN-16-2310","article-title":"Cellular and molecular identity of tumor-associated macrophages in glioblastoma","volume":"77","author":"Chen","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12015-008-9021-5","article-title":"Glioma formation, cancer stem cells, and Akt signaling","volume":"4","author":"Hambardzumyan","year":"2008","journal-title":"Stem Cell Rev."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226444","article-title":"Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model","volume":"15","author":"McKelvey","year":"2020","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.canlet.2025.218216_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj3301","article-title":"Hypoxia coordinates the spatial landscape of myeloid cells within glioblastoma to affect survival","volume":"10","author":"Haley","year":"2024","journal-title":"Sci. Adv."},{"issue":"8060","key":"10.1016\/j.canlet.2025.218216_bib80","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib81","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/brain\/awq042","article-title":"A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2\u03b1","volume":"133","author":"Seidel","year":"2010","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib82","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib83","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.stem.2016.12.001","article-title":"Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression","volume":"20","author":"Alvarado","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"issue":"10, Part B","key":"10.1016\/j.canlet.2025.218216_bib85","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.bbadis.2017.05.020","article-title":"White matter damage after traumatic brain injury: a role for damage associated molecular patterns","volume":"1863","author":"Braun","year":"2017","journal-title":"Biochim. Biophys. Acta BBA Mol. Basis Dis."},{"key":"10.1016\/j.canlet.2025.218216_bib86","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11635","article-title":"HIF-1\u03b1-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity","volume":"7","author":"Semba","year":"2016","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib87","article-title":"Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma","volume":"4","author":"Pang","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib88","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib89","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12964-024-01523-y","article-title":"Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages","volume":"22","author":"Tankov","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib90","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12951-024-02888-5","article-title":"Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway","volume":"22","author":"Xue","year":"2024","journal-title":"J. Nanobiotechnol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib91","doi-asserted-by":"crossref","first-page":"C487","DOI":"10.1152\/ajpcell.00124.2024","article-title":"Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner","volume":"327","author":"Li","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.canlet.2025.218216_bib92","doi-asserted-by":"crossref","unstructured":"C. Sun, S. Wang, Z. Ma, J. Zhou, Z. Ding, G. Yuan, et al., Neutrophils in glioma microenvironment: from immune function to immunotherapy, Front. Immunol. 15 (2024 May 8) 1393173.","DOI":"10.3389\/fimmu.2024.1393173"},{"issue":"22","key":"10.1016\/j.canlet.2025.218216_bib93","first-page":"5822","article-title":"Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells","volume":"59","author":"Xu","year":"1999","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib94","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1038\/s41467-018-07505-2","article-title":"Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression","volume":"9","author":"Rice","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/ijms21010287","article-title":"Neutrophil metabolic shift during their lifecycle: impact on their survival and activation","volume":"21","author":"Injarabian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218216_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.freeradbiomed.2023.06.027","article-title":"Acrolein produced by glioma cells under hypoxia inhibits neutrophil AKT activity and suppresses anti-tumoral activities","volume":"207","author":"Tsai","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"6679","key":"10.1016\/j.canlet.2025.218216_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf6493","article-title":"Deterministic reprogramming of neutrophils within tumors","volume":"383","author":"Ng","year":"2024","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib98","first-page":"1444","article-title":"Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells","volume":"173","author":"Viguier","year":"1950","journal-title":"J. Immunol. Baltim Md"},{"key":"10.1016\/j.canlet.2025.218216_bib99","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib101","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.celrep.2019.03.029","article-title":"HIF-1\u03b1 is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of tregs in glioblastoma","volume":"27","author":"Miska","year":"2019","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187314","article-title":"Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells","volume":"12","author":"Sethumadhavan","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib103","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/glia.21136","article-title":"The brain tumor microenvironment","volume":"59","author":"Charles","year":"2011","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016195","article-title":"Hypoxia potentiates glioma-mediated immunosuppression","volume":"6","author":"Wei","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib105","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers"},{"issue":"7851","key":"10.1016\/j.canlet.2025.218216_bib106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib107","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol. Immunother CII"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-020-02667-4","article-title":"Hypoxia and the phenomenon of immune exclusion","volume":"19","author":"Pietrobon","year":"2021","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib109","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1349-7006.2012.02259.x","article-title":"Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia","volume":"103","author":"Lin","year":"2012","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/0008-5472.CAN-15-0977","article-title":"Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis","volume":"76","author":"Ye","year":"2016","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib111","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib112","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/0008-5472.CAN-18-2545","article-title":"Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis","volume":"79","author":"Jeong","year":"2019","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib113","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1084\/jem.20100587","article-title":"HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment","volume":"207","author":"Corzo","year":"2010","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib114","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.canlet.2025.218216_bib115","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1158\/0008-5472.CAN-15-0405","article-title":"Tumor-promoting effects of myeloid-derived suppressor cells are potentiated by hypoxia-induced expression of miR-210","volume":"75","author":"Noman","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib116","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3892\/ijo.2012.1630","article-title":"Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1\u03b1-dependent manner","volume":"41","author":"Yamada","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib117","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.canlet.2025.218216_bib118","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3389\/fimmu.2018.02358","article-title":"Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration","volume":"9","author":"Parodi","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.canlet.2025.218216_bib119","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","article-title":"Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance","volume":"20","author":"Zheng","year":"2019","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.canlet.2025.218216_bib120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/cells14070494","article-title":"Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions","volume":"14","author":"Tang","year":"2025","journal-title":"Cells"},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.218216_bib121","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.2546","article-title":"A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients","volume":"29","author":"Goetz","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.218216_bib122","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.2538","article-title":"Phase Ib clinical trial of OKN-007 in recurrent malignant glioma","volume":"38","author":"Battiste","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"7_Supplement","key":"10.1016\/j.canlet.2025.218216_bib123","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT201","article-title":"Abstract CT201: phase 2 clinical trial of OKN-007 in recurrent malignant glioma","volume":"84","author":"Battiste","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-024-06492-1","article-title":"Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach","volume":"15","author":"Bayona","year":"2024","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.canlet.2025.218216_bib125","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1158\/1078-0432.CCR-09-1650","article-title":"Inhibiting the hypoxia response for cancer therapy: the new kid on the block","volume":"15","author":"Koh","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.605.65.2","article-title":"Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway","volume":"65","author":"Tan","year":"2005","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2025.218216_bib127","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1158\/0008-5472.CAN-04-2116","article-title":"Schedule-dependent inhibition of hypoxia-inducible Factor-1\u03b1 protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.218216_bib128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(22)00599-X","article-title":"Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial","volume":"23","author":"Spinazzi","year":"2022","journal-title":"Lancet Oncol."},{"issue":"50","key":"10.1016\/j.canlet.2025.218216_bib129","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1\u03b1 synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"34","key":"10.1016\/j.canlet.2025.218216_bib130","doi-asserted-by":"crossref","first-page":"56110","DOI":"10.18632\/oncotarget.18125","article-title":"Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib131","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib132","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.235","article-title":"The novel hypoxia-inducible factor-1\u03b1 inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth","volume":"8","author":"Ban","year":"2017","journal-title":"Cell Death Dis."},{"issue":"12","key":"10.1016\/j.canlet.2025.218216_bib133","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jnen\/nlx088","article-title":"LBH589 inhibits glioblastoma growth and angiogenesis through suppression of HIF-1\u03b1 expression","volume":"76","author":"Yao","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib134","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.218216_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3076","article-title":"Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1\u03b1","volume":"28","author":"Tibes","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.canlet.2025.218216_bib136","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-12-0861","article-title":"Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1\u03b1 interaction with cofactors p300\/CBP","volume":"18","author":"Yin","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2025.218216_bib137","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1158\/0008-5472.CAN-05-1235","article-title":"Echinomycin, a small-molecule inhibitor of hypoxia-inducible Factor-1 DNA-binding activity","volume":"65","author":"Kong","year":"2005","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cells14060407","article-title":"Angiogenesis in Glioblastoma\u2014treatment approaches","volume":"14","author":"Nowacka","year":"2025","journal-title":"Cells"},{"issue":"28","key":"10.1016\/j.canlet.2025.218216_bib139","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1634\/theoncologist.2018-0290","article-title":"A randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma","volume":"24","author":"Brandes","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.canlet.2025.218216_bib141","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/neuonc\/noae033","article-title":"Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma","volume":"26","author":"Hiller-Vallina","year":"2024","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib142","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept\u2014A decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2025.218216_bib143","author":"Phase"},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib144","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.13.68","article-title":"Ramucirumab: a novel antiangiogenic agent","volume":"9","author":"Wadhwa","year":"2013","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.218216_bib145","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-019-03236-6","article-title":"Phase II study of Dovitinib in recurrent glioblastoma","volume":"144","author":"Sharma","year":"2019","journal-title":"J. Neuro Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae241","article-title":"The STELLAR trial: a phase II\/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma","volume":"6","author":"Janssen","year":"2024","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib147","article-title":"Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","volume":"2","author":"Chen","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"26","key":"10.1016\/j.canlet.2025.218216_bib148","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.canlet.2025.218216_bib149","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1200\/JCO.2008.16.9235","article-title":"Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European organisation for research and treatment of cancer brain tumor group study","volume":"26","author":"Raymond","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib150","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noq025","article-title":"Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American brain tumor consortium study 06-02)","volume":"12","author":"Iwamoto","year":"2010","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.218216_bib151","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib152","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/neuonc\/noae053","article-title":"Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial","volume":"26","author":"Roth","year":"2024","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib153","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/cancers15030830","article-title":"Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib154","article-title":"Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab","volume":"2","author":"Patel","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10555-019-09792-7","article-title":"Causes, consequences, and therapy of tumors acidosis","volume":"38","author":"Pillai","year":"2019","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.canlet.2025.218216_bib156","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/0008-5472.CAN-07-5575","article-title":"Bicarbonate increases tumor pH and inhibits spontaneous metastases","volume":"69","author":"Robey","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218216_bib157","article-title":"Buffer therapy \u2192 buffer diet","author":"Pilot","year":"2018","journal-title":"J. Nutr. Food Sci."},{"key":"10.1016\/j.canlet.2025.218216_bib158","article-title":"A phase I\/II open-label, non-randomized dose escalation study of immunoconjugate L-DOS47 as a monotherapy in non-squamous non-small cell lung cancer patients","year":"2019","journal-title":"Nat. Libr. Med."},{"key":"10.1016\/j.canlet.2025.218216_bib160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.drup.2015.08.004","article-title":"Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach","volume":"23","author":"Taylor","year":"2015","journal-title":"Drug Resist. Updates"},{"issue":"9","key":"10.1016\/j.canlet.2025.218216_bib161","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cells8090984","article-title":"The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma","volume":"8","author":"Fields","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.canlet.2025.218216_bib162","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/art.24629","article-title":"A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models","volume":"60","author":"Baragi","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib163","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1215\/15228517-2008-001","article-title":"Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM","volume":"10","author":"Du","year":"2008","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218216_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151815","article-title":"Comparative analysis of matrix metalloproteinase family members reveals that MMP9 predicts survival and response to temozolomide in patients with primary glioblastoma","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218216_bib165","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919864247","article-title":"TIMP-3 as a therapeutic target for cancer","volume":"11","author":"Su","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.218216_bib166","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18632\/oncotarget.28691","article-title":"Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells","volume":"16","author":"Taheri","year":"2025","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib167","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","article-title":"Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy","volume":"9","author":"Zhao","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib168","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.canlet.2025.218216_bib169","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.3324\/haematol.2023.284795","article-title":"Blockade of the CD47\/SIRP\u03b1 checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab","volume":"109","author":"Biedermann","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.canlet.2025.218216_bib170","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.jid.2019.11.018","article-title":"A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with Anti\u2013PD-1 in a murine model of cutaneous T-Cell lymphoma (CTCL)","volume":"140","author":"Wu","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2025.218216_bib171","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.007","article-title":"CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in phase 1 study","volume":"28","author":"Powderly","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib172","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jhep.2015.02.009","article-title":"Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through toll like receptor 9","volume":"63","author":"Liu","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2025.218216_bib173","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2018.11.005","article-title":"Suppression of HMGB1 released in the glioblastoma tumor microenvironment reduces tumoral edema","volume":"12","author":"Hong","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib174","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40824-023-00391-w","article-title":"Inhibition of DAMP actions in the tumoral microenvironment using lactoferrin-glycyrrhizin conjugate for glioblastoma therapy","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater. Res."},{"issue":"7","key":"10.1016\/j.canlet.2025.218216_bib175","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177141","article-title":"Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment","volume":"9","author":"Hatae","year":"2024","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib176","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.ymthe.2025.04.037","article-title":"Engineering TME-gated inducible CAR-T cell therapy for solid tumors","volume":"33","author":"Nguyen","year":"2025","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib177","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib178","first-page":"266","article-title":"Modeling physiological events in 2D vs. 3D cell culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiol. Bethesda Md"},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib179","article-title":"Mouse models of glioblastoma for the evaluation of novel therapeutic strategies","volume":"3","author":"Haddad","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"issue":"5","key":"10.1016\/j.canlet.2025.218216_bib180","article-title":"Differences in innate immune response between man and mouse","volume":"34","author":"Zschaler","year":"2014","journal-title":"Crit. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218216_bib181","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-15-2402","article-title":"A three-dimensional organoid culture system derived from human glioblastomas recapitulates the hypoxic gradients and cancer stem cell heterogeneity of tumors found in vivo","volume":"76","author":"Hubert","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218216_bib182","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates Inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.canlet.2025.218216_bib183","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ad5764","article-title":"Development of an organ-on-chip model for the detection of volatile organic compounds as potential biomarkers of tumour progression","volume":"16","author":"Bayona","year":"2024","journal-title":"Biofabrication"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:40:53Z","timestamp":1792096853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":182,"alternative-id":["S0304383525007888"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218216","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor microenvironment in glioblastoma: The central role of the hypoxic\u2013necrotic core","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218216"}}